Multiple viral hepatitis in injection drug users and associated risk factors

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 1, 2007, Pages 80-85

  Reimer, Jens ^a,e   Lorenzen, Juergen ^a   Baetz, Bernhard ^b   Fischer, Benedikt ^d   Rehm, Juergen ^d   Haasen, Christian ^a   Backmund, Markus ^c  

^a UNIVERSITY OF HAMBURG   (Germany)

^b Psychiatric Hospital Guetersloh   (Germany)

^c Klinikum Schwabing   (Germany)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Coinfection; HAV; HBV; HCV; Injection drug use; Risk factor

Indexed keywords

BIOCHEMICAL MARKER; COCAINE; DIAMORPHINE; HEPATITIS A ANTIBODY; HEPATITIS B ANTIBODY; HEPATITIS C ANTIBODY; OPIATE;

ADULT; AGE DISTRIBUTION; ANALYSIS OF VARIANCE; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DETOXIFICATION; DISEASE DURATION; DRUG DEPENDENCE TREATMENT; DRUG USE; FEMALE; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; INJECTION; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PRIORITY JOURNAL; RISK FACTOR; SEROLOGY; VIRUS HEPATITIS;

EID: 33845638732     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04358.x     Document Type: Article

References (38)

1. Fischer B, Hayden B, Rehm J, Krajden M, Reimer J. Injection drug use and the hepatitis C virus: considerations for a targeted treatment approch: the case study of Canada. J. Urban Health 2004; 81: 428-47.
2. Lee WM. Hepatitis B virus infection. N. Engl. J. Med. 1997; 337: 1733-45.
3. Edeh J, Spalding P. Screening for HIV, HBV and HCV markers among drug users in treatment in rural south-east England. J. Public Health. Med. 2000; 22: 531-9.
4. Torbenson M, Kannangai R, Astemborski J, Strathdee SA, Vlahov D, Thomas DL. High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology 2004; 39: 51-7.
5. Backmund M, Meyer K, Wachtler M, Eichenlaub D. Hepatitis C virus infection in injection drug users in Bavaria: risk factors for seropositivity. Eur. J. Epidemiol. 2003; 18: 563-8.
6. Coppola RC, Manconi PE, Piro R, Di Martino ML, Masia G. HCV, HIV, HBV and HDV infections in intravenous drug addicts. Eur. J. Epidemiol. 1994; 10: 279-83.
7. Fuglsang T, Fouchard JR, Ege P. Prevalence of HIV, hepatitis C and B among drug users in the city of Copenhagen. Ugeskr. Laeger 2000; 162: 3860-4.
8. Garfein RS, Doherty MC, Monterroso ER. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1998; 18 (Suppl. 1): 11-19.
9. Matheï C, Buntinx F, van Damme P. Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: a systematic review. J. Viral. Hepat. 2002; 9: 157-73.
10. Patti AM, Santi AL, Pompa MG et al. Viral hepatitis and drugs: a continuing problem. Int. J. Epidemiol. 1993; 22: 135-9.
11. Klusonova H, Steponova V, Cizek J, Pliskova L. Viral hepatitis in users of addictive drugs in the Czech Republic. Epidemiol. Mikrobiol. Immunol. 2004; 53: 47-54 (in Czech).
12. Pallas JR, Farinas-Alvarez C, Prieto D, Delgado-Rodriguez M. Coinfections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users. Eur. J. Epidemiol. 1999; 15: 699-704.
13. Villano SA, Nelson KE, Vlahov D, Purcell RH, Saah AJ, Thomas DL. Hepatitis A among homosexual men and injection drug users: more evidence for vaccination. Clin. Infect. Dis. 1997; 25: 726-8.
14. Koff RS. Risks associated with hepatitis A and hepatitis B in patients with hepatitis C. J. Clin. Gastroenterol. 2001; 33: 20-6.
15. Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am. J. Gastroenterol. 1995; 90: 201-5.
16. Mohamed Ael S, al Karawi MA, Mesa GA. Dual infection with hepatitis C and B viruses: clinical and histological study. Hepatogastroenterology 1997; 44: 1404-6.
17. Zarski JP, Bohn B, Bastie A et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J. Hepatol. 1998; 28: 27-33.
18. Alberti A, Pontisso P, Chemello L et al. The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J. Hepatol. 1995; 22: 38-41.
19. Ilan Y, Ashur Y, Tur-Kaspa R, Shouval D. Chronic hepatitis C virus infection with exposure to hepatitis B virus. Isr. J. Med. Sci. 1994; 30: 259-63.
20. Feray C, Gigou M, Samuel D et al. Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. Gastroenterol. 1993; 104: 549-55.
21. Vento S. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. J. Viral. Hepat. 2000; 7 (Suppl. 1): 7-8.
22. Syed NA, Hearing SD, Shaw IS et al. Outbreak of hepatitis A in the injecting drug user and homeless populations in Bristol: control by a targeted vaccination programme and possible parenteral transmission. Eur. J. Gastroenterol. Hepatol. 2003; 15: 901-6.
23. Zeldis JB, Jain S, Kuramato IK et al. Seroepidemiology of viral infections among intravenous drug users in northern California. West. J. Med. 1992; 156: 30-5.
24. Craine N, Walker AM, Williamson AM, Brown A, Hope VD. Hepatitis B and hepatitis C seroprevalence and risk behaviour among community-recruited drug injectors in North West Wales. Commun. Dis. Public Health 2004; 7: 216-19.
25. McHutchison JG. Understanding hepatitis C. Am. J. Manag. Care 2004; 10 (Suppl. 2): S21-9.
26. Tahan V, Karaca C, Yildirim B et al. Sexual transmission of HCV between spouses. Am. J. Gastroenterol. 2005; 100: 821-4.
27. Leino T, Leinikki P, Hyypia T et al. Hepatitis A outbreak amongst intravenous amphetamin abusers in Finland. Scand. J. Infect. Dis. 1997; 29: 213-16.
28. Grinde B, Stene-Johansen K, Sharma B, Hoel T, Jensenius M, Skaug K. Characterisation of an epidemic of hepatitis A virus involving intravenous drug abusers: infection by needle sharing? J. Med. Virol. 1997; 53: 69-75.
29. Hutin YJF, Sabin KM, Hutwanger LC et al. Multiple modes of hepatitis A virus transmission among methamphetamine users. Am. J. Epidemiol. 2000; 152: 186-92.
30. Thierfelder W, Hellenbrand W, Meisel H, Schreier E, Dortschy R. Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health Interview and Examination Survey 1998. Eur. J. Epidemiol. 2001; 17: 429-35.
31. Darke S, Hall W, Ross M, Wodak A. Benzodiazepines use and HIV risk-taking behaviour among injecting drug users. Drug Alcohol Depend. 1992; 31: 31-6.
32. Lejuez CW, Bornovalova MA, Daughters SB, Curtin JJ. Differences in impulsivity and sexual risk behaviour among inner-city crack/cocaine users and heroin users. Drug Alcohol Depend. 2005; 77: 169-75.
33. Mathei C, Robaeys G, van Damme P, Buntinx F, Verrando R. Prevalence of hepatitis C in drug users in Flanders: determinants and geographic differences. Epidemiol. Infect. 2005; 133: 127-36.
34. Stene-Johansen K, Skaug K, Blystad H, Grinde B. A unique hepatitis A virus strain caused an epidemic in Norway associated with intravenous drug abuse. The Hepatitis A Study Group. Scand. J. Infect. Dis. 1998; 30: 35-8.
35. Diel R, Schneider S. Transmission of hepatitis A in Hamburg, Germany, 1998-99. A prospective population based study. Eur. J. Epidemiol. 2001; 17: 175-82.
36. Fuller CM, Vlahov D, Ompad DC, Shah N, Arria A, Strathdee SA. High-risk behaviors associated with transition from illicit noninjection drug use among adolescent and young adult drug users: a case-control study. Drug Alcohol Depend. 2002; 66: 189-98.
37. [No authors listed]. Hepatitis B vaccination for injection drug users: Pierce County, Washington, 2000. MMWR Morb. Mortal. Wkly Rep. 2001; 50: 388-90.
38. [No authors listed]. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb. Mortal. Wkly Rep. 1996; 45: 1-30.